Genovis AB (publ.)
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an… Read more
Genovis AB (publ.) (GENO) - Net Assets
Latest net assets as of December 2025: Skr271.52 Million SEK
Based on the latest financial reports, Genovis AB (publ.) (GENO) has net assets worth Skr271.52 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr377.93 Million) and total liabilities (Skr106.41 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr271.52 Million |
| % of Total Assets | 71.84% |
| Annual Growth Rate | 24.36% |
| 5-Year Change | 138.19% |
| 10-Year Change | 1646.69% |
| Growth Volatility | 51.76 |
Genovis AB (publ.) - Net Assets Trend (2008–2025)
This chart illustrates how Genovis AB (publ.)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Genovis AB (publ.) (2008–2025)
The table below shows the annual net assets of Genovis AB (publ.) from 2008 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr271.52 Million | +19.10% |
| 2024-12-31 | Skr227.97 Million | +19.48% |
| 2023-12-31 | Skr190.81 Million | +51.86% |
| 2022-12-31 | Skr125.65 Million | +10.23% |
| 2021-12-31 | Skr113.99 Million | +30.78% |
| 2020-12-31 | Skr87.17 Million | +144.70% |
| 2019-12-31 | Skr35.62 Million | +36.63% |
| 2018-12-31 | Skr26.07 Million | +43.35% |
| 2017-12-31 | Skr18.19 Million | +16.99% |
| 2016-12-31 | Skr15.55 Million | +76.21% |
| 2015-12-31 | Skr8.82 Million | -39.51% |
| 2014-12-31 | Skr14.58 Million | -55.92% |
| 2013-12-31 | Skr33.09 Million | +142.69% |
| 2012-12-31 | Skr13.63 Million | -24.31% |
| 2011-12-31 | Skr18.01 Million | +18.24% |
| 2010-12-31 | Skr15.23 Million | +40.29% |
| 2009-12-31 | Skr10.86 Million | +62.61% |
| 2008-12-31 | Skr6.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genovis AB (publ.)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5140165700.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr16.52 Million | 6.08% |
| Other Components | Skr255.01 Million | 93.92% |
| Total Equity | Skr271.52 Million | 100.00% |
Genovis AB (publ.) Competitors by Market Cap
The table below lists competitors of Genovis AB (publ.) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ADAMS RES. EN. INC.DL-10
F:5QT
|
$81.59 Million |
|
Citra Putra Realty Tbk PT
JK:CLAY
|
$81.67 Million |
|
P.S.P. Specialties Public Company Limited
BK:PSP
|
$81.67 Million |
|
Martin Midstream Partners LP
NASDAQ:MMLP
|
$81.68 Million |
|
Salim Ivomas Pratama Tbk
JK:SIMP
|
$81.57 Million |
|
MOTORPOINT GRP WI LS-01
F:1X4
|
$81.57 Million |
|
Savannah Resources Plc
PINK:SAVNF
|
$81.57 Million |
|
GFLT
PINK:GFLT
|
$81.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genovis AB (publ.)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 227,972,000 to 271,524,000, a change of 43,552,000 (19.1%).
- Net income of 23,498,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 6,881,999.
- Other factors increased equity by 26,935,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr23.50 Million | +8.65% |
| Other Comprehensive Income | Skr-6.88 Million | -2.53% |
| Other Changes | Skr26.94 Million | +9.92% |
| Total Change | Skr- | 19.10% |
Book Value vs Market Value Analysis
This analysis compares Genovis AB (publ.)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.92x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.81x to 3.92x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | Skr4.25 | Skr16.20 | x |
| 2009-12-31 | Skr4.70 | Skr16.20 | x |
| 2010-12-31 | Skr2.90 | Skr16.20 | x |
| 2011-12-31 | Skr2.04 | Skr16.20 | x |
| 2012-12-31 | Skr0.91 | Skr16.20 | x |
| 2013-12-31 | Skr1.58 | Skr16.20 | x |
| 2014-12-31 | Skr0.63 | Skr16.20 | x |
| 2015-12-31 | Skr0.29 | Skr16.20 | x |
| 2016-12-31 | Skr0.33 | Skr16.20 | x |
| 2017-12-31 | Skr0.31 | Skr16.20 | x |
| 2018-12-31 | Skr0.42 | Skr16.20 | x |
| 2019-12-31 | Skr0.56 | Skr16.20 | x |
| 2020-12-31 | Skr1.34 | Skr16.20 | x |
| 2021-12-31 | Skr1.74 | Skr16.20 | x |
| 2022-12-31 | Skr1.92 | Skr16.20 | x |
| 2023-12-31 | Skr2.91 | Skr16.20 | x |
| 2024-12-31 | Skr3.48 | Skr16.20 | x |
| 2025-12-31 | Skr4.13 | Skr16.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genovis AB (publ.) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.65%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.22%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.39x
- Recent ROE (8.65%) is above the historical average (-73.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -406.61% | -7151.16% | 0.03x | 2.25x | Skr-27.82 Million |
| 2009 | -161.71% | -1780.43% | 0.07x | 1.36x | Skr-18.64 Million |
| 2010 | -74.13% | -707.48% | 0.09x | 1.17x | Skr-12.81 Million |
| 2011 | -75.56% | -476.46% | 0.13x | 1.19x | Skr-15.41 Million |
| 2012 | -146.08% | -327.50% | 0.33x | 1.33x | Skr-21.28 Million |
| 2013 | -47.91% | -177.88% | 0.22x | 1.25x | Skr-19.16 Million |
| 2014 | -151.19% | -267.19% | 0.42x | 1.34x | Skr-23.51 Million |
| 2015 | -225.64% | -150.02% | 0.78x | 1.92x | Skr-20.79 Million |
| 2016 | -96.69% | -81.06% | 0.85x | 1.41x | Skr-16.59 Million |
| 2017 | -43.71% | -34.76% | 0.87x | 1.45x | Skr-9.77 Million |
| 2018 | -6.56% | -4.95% | 0.91x | 1.45x | Skr-4.32 Million |
| 2019 | 26.81% | 15.77% | 1.23x | 1.38x | Skr5.99 Million |
| 2020 | 7.40% | 10.56% | 0.57x | 1.22x | Skr-2.27 Million |
| 2021 | 21.74% | 26.64% | 0.66x | 1.24x | Skr13.38 Million |
| 2022 | 8.91% | 10.93% | 0.68x | 1.20x | Skr-1.37 Million |
| 2023 | 32.23% | 38.87% | 0.55x | 1.51x | Skr42.42 Million |
| 2024 | 14.44% | 25.25% | 0.40x | 1.44x | Skr10.12 Million |
| 2025 | 8.65% | 18.22% | 0.34x | 1.39x | Skr-3.65 Million |
Industry Comparison
This section compares Genovis AB (publ.)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genovis AB (publ.) (GENO) | Skr271.52 Million | -406.61% | 0.39x | $81.58 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |